This Week in Life Sciences: 52 New Companies, 14 Worth Watching Closely

The weekly industry diff (comparing the 2026-06-18 snapshot of 14,321 companies against today’s 14,334) flagged 60 raw additions and 47 raw removals. After matching against our internal jobs database, 52 companies are genuinely new to the life-sciences landscape this week — meaning they were not present in our prior company table at all. We ran deep research on every single one of them, surfacing founders, funding rounds, lead investors, pipeline stage, and modality bets.

Most of the 52 are small services companies, distributors, or stealth-mode startups with no public footprint. A handful are rebrandings (Rage Bio → Atisama Therapeutics; Verge Genomics → Verge Labs after a clinical-stage pivot). And a small but interesting cluster — roughly a dozen — are early-stage drug developers or medtech companies with real funding momentum, big-name backers, or genuinely differentiated science. We also surfaced a few established-pharma subsidiaries (Yoshindo Holdings, Zydus Pharmaceuticals USA, Zydus Therapeutics) that the industry snapshot is tracking separately from their parents.

Below are the ones worth tracking.

The Headline: Cavalry Biosciences — $75M Series B for Precision IGF-1

Cavalry Biosciences is the most heavily-funded newcomer of the week. On June 8, 2026, the company disclosed a $75 million Series B to take its engineered IGF-1 (insulin-like growth factor 1) pipeline into multiple clinical readouts in retinal and muscular disorders.

The core problem Cavalry is solving is one IGF-1 researchers have wrestled with for decades: IGF-1 is the body’s most powerful growth factor, capable of repairing retina, muscle, nerve, and other tissues — but it’s also short-lived in circulation, broadly distributed, and burdened by systemic side effects when administered as a drug. Cavalry’s platform re-engineers IGF-1 itself so that it drives repair only where it’s needed.

The company is led by CEO Preston Klassen (formerly of Orexigen and Mira) and co-founder/CSO Tim Stowe. Their pipeline is positioned around two of the harder tissue-selective indications — retinal degeneration and muscular disorders — where IGF-1’s regenerative potential has been known for years but unmedicable due to the systemic-exposure problem.

$75M is a meaningful Series B by 2026 standards, and Cavalry’s positioning around an old, well-validated target with a new delivery solution is the kind of thesis VCs fund when they want clinical risk minimized.

A close second in the funding-leaderboard this week is Ethyreal Bio, which emerged from stealth with $101M Series A+B combined for anti-TSHR antibodies targeting Amgen’s Tepezza market. See the Ethyreal Bio section below.

Wondercel Therapeutics — Off-the-Shelf CAR-T, From Legend Biotech’s Scientific Founder

Wondercel Therapeutics is a new cell-therapy company built by Frank Fan, the scientific founder of Legend Biotech (the $CARVYsma / ciltacabtagene autoleucel company). Wondercel is developing an off-the-shelf (allogeneic) CAR-T platform aimed at solid tumors, with an early investigator-initiated trial (NCT06653023) evaluating a GPC3-targeting candidate in hepatocellular carcinoma and lung cancer.

Frank Fan’s return to cell therapy is notable for two reasons. First, Legend proved autologous CAR-T can clear hard heme targets — but autologous manufacturing is the bottleneck for solid tumors, where scale and cost are dealbreakers. Second, allogeneic platforms (all CAR-T from healthy donor cells, not the patient) have so far been mostly preclinical or limited to heme indications. A GPC3-targeted off-the-shelf program aimed at HCC and lung is a bolder scientific bet than the allogeneic pack has generally taken.

The name change is recent (Wondercel was disclosed in the Legend founder’s relaunch press around ASCO 2026), and funding details are still emerging — but the founder pedigree alone earns Wondercel a slot on this watchlist.

Crownlands — Open-Source Single-Cell Atlas of Living Human Neurons

Crownlands released on June 10, 2026 what they describe as the largest open-source dataset of living patient cells for Alzheimer’s and neuroscience research: a 4-million-cell single-cell transcriptomic atlas built from olfactory neurons collected from 200+ living donors (including Alzheimer’s patients and healthy controls) via a proprietary nasal biopsy method, processed through standardized pipelines and made available on the CZ CELLxGENE platform.

The dataset is a striking open-science move: it’s the kind of raw, longitudinal, human primary material that biotech AI teams have been begging for, and Crownlands is releasing it for free. The company is using the dataset to build its own pipeline in neurodegenerative and CNS disease, but the publication-first stance is what makes them notable.

Crownlands is a 2024 startup backed by Caffeinated Capital, First Round Capital, and Scribble Ventures (round size undisclosed). They emerged from stealth around the dataset release. The combination of (a) living human neurons — not iPSC-derived proxies — and (b) free public release puts Crownlands in a similar narrative slot to what Mosaic Therapeutics or Recursion’s open-data initiatives were a few years ago.

EndoRobotics — Olympus Just Signed Global Distribution

On May 4, 2026, Olympus Corporation announced an exclusive global distribution agreement with EndoRobotics, a South Korea-based medical device company building robotic systems for endoscopic submucosal dissection (ESD) — the procedure used to remove early-stage tumors and precancerous lesions from the GI tract lining. The deal includes an Olympus option to acquire EndoRobotics.

For a previously-stealthy endoscopic robotics startup, landing global distribution with Olympus (the dominant player in GI endoscopy) is the single biggest commercial milestone a company in this niche can hit. It validates the technology, opens immediate sales channels, and sets up a likely acquisition target.

The South Korean medtech ecosystem — think Lunit, JW Medical, Medipost, LivsMed — has produced a series of endoscopic and surgical robotics wins over the past few years. EndoRobotics is the latest, and possibly the most strategic, given the Olympus deal.

Neopharmed Gentili — $250M BioCryst Acquisition Closes Its Year

While not technically a “new company,” Neopharmed Gentili appeared in this week’s industry diff after closing its $250M upfront + $14M earnout acquisition of BioCryst’s European ORLADEYO (berotralstat) business on June 27, 2025 — a rare-disease asset for hereditary angioedema generating ~€50M in European sales growing 30%+ YoY with an established specialty sales infrastructure.

Neopharmed Gentili is the specialty pharma arm of the Del Bono family’s Mediolanum Farmaceutici Group, majority-owned by Ardian since 2019. The ORLADEYO buy is a textbook Ardian-style value-creation move: take a cash-flowing European specialty pharma, give it a US/European rare-disease asset, and compound growth. The company is now actively hunting for further bolt-ons in rare disease across Europe.

For the jobs-focused reader: Neopharmed Gentili is hiring in commercial, regulatory, and medical affairs roles to support the European ORLADEYO rollout.

Neptune Medical — $97M Series D for GI Robotics

Neptune Medical is a Burlingame-based medtech that has been raising in the $90–100M range repeatedly — most recently a $97M Series D (Fierce Biotech coverage). Founded in 2016 by Alex Tilson, Neptune’s core technology is a dynamic rigidizing overtube for endoscope control, with a recently-launched Jupiter endovascular subsidiary that extends the same mechanical platform into vascular procedures.

Neptune has now raised well over $200M cumulatively across multiple Series. The Jupiter endovascular spin-out is the most interesting new development — it suggests the rigidizing-tube IP has legs beyond GI endoscopy into catheter-based vascular interventions.

Tulyp Medical — From Sofinnova’s Accelerator to FDA Submission

Tulyp Medical emerged from stealth in November 2025 with an FDA submission for a patented pressure-driven perfusion system for vascular surgery. It is the 13th company spun out of Sofinnova Partners’ MD Start accelerator, which is one of the most consistent medtech seed-creators in Europe.

Sofinnova MD Start graduates tend to follow a tight pattern: emerge from stealth with an FDA or CE submission, raise a Series A inside 12 months, and either get acquired by a strategic or IPO within 3–4 years. Tulyp is on that track now.

Atisama Therapeutics — $21.8M Series A, Inhaled SSOs in Phase 1

Atisama Therapeutics is the new identity of Rage Bio, an Australian clinical-stage biotech developing inhaled splice-switching oligonucleotides (SSOs) for COPD and inflammatory disease. The rebrand was announced on May 14, 2026. The company has raised $21.8M Series A, backed by IP Group, and is actively enrolling in Phase 1 multiple-ascending-dose (MAD) cohorts with RB042 as of May 2026.

SSOs are chemically similar to ASOs but act by modulating mRNA splicing rather than degrading transcripts. The platform has been validated by Spinraza (nusinersen) in spinal muscular atrophy, but Atisama is one of the few trying to extend it to chronic inhaled indications — a much harder PK problem but with enormous potential if it works. Active Phase 1 enrollment with a backing syndicate that includes IP Group is one of the strongest validation signals in this week’s batch.

Reprogram Biosciences — $6M Seed to Turn Tumors Into Immune Cells

Reprogram Biosciences closed a $6M seed round on May 27, 2026 led by 1517 Fund (Peter Thiel’s fund). The concept is striking: deliver mRNA-encoded gene combinations directly into a tumor and reprogram the tumor cells into immune cells in situ.

This is a different mechanistic bet than checkpoint inhibitors or CAR-T — instead of training the immune system to recognize tumors, Reprogram is trying to convert the tumor cells themselves into antigen-presenting immune cells, in real time, inside the body. The preclinical data is early but the framing is bold enough to draw seed capital in a brutal funding environment.

The company is based in San Carlos, CA and operates as a preclinical oncology biotech.

Bonito Biosciences — Programmable Oligotherapeutics With $29.5M Raised

Bonito Biosciences has raised $29.5M to date, with Lightstone Ventures, Anterra Capital, and JAZZ Venture Partners participating in the seed round (closed May 31, 2024). Founded in 2022 in Waltham, MA by Richard Wagner (CEO), the company is building a tissue-selective delivery platform for oligonucleotide therapeutics, combining functional selections with giga-scale encoded libraries to generate proprietary delivery-ligand datasets.

Bonito’s bet is that the bottleneck for oligonucleotide drugs — which now include Spinraza, Leqvio, Wainua, and others — is no longer the chemistry but the delivery to the right tissue at the right dose without off-target effects. If the platform holds up, Bonito becomes an obvious out-licensing play to anyone working on siRNA, ASO, or SSO programs.

Ethyreal Bio — $101M A+B to Take On Amgen’s Tepezza

The biggest funding story of the week that we initially missed: Ethyreal Bio (ethyrealbio.com) emerged from stealth in June 2026 with $101M total raised across a Series A and a Series B. The Series B was co-led by Atlas Venture and Medicxi Ventures, with Avoro Capital also participating. The company is developing ETHY-001, an anti-TSHR antibody for thyroid eye disease (TED) and Graves’ disease — directly targeting the same market as Amgen’s Tepezza (teprotumumab), which is one of the largest rare-disease drug launches of the past several years ($3.7B+ in 2024 sales).

Tepezza is a landmark product but has well-known limitations: it requires 8 IV infusions over 24 weeks, has hearing-related side effects in a non-trivial fraction of patients, and faces active biosimilar threats as the IP cliff approaches. A differentiated anti-TSHR antibody that can match Tepezza’s efficacy with subcutaneous dosing or a shorter course would have obvious commercial value.

Atlas Venture + Medicxi as co-leads is a high-credibility European/American VC syndicate for a thyroid autoimmunity asset, and the $101M total raise (most of it pre-Phase 1) is one of the largest stealth-to-launch rounds in this week’s batch.

HydroGene Therapeutics — Non-Viral Gene Therapy Without AAV’s Limitations

HydroGene Therapeutics (Houston, TX) presented NHP data at ASGCT 2026 showing that its non-viral DNA delivery platform achieves expression and durability comparable to commercial AAV products — without AAV’s immunogenicity, payload-size, or manufacturing constraints. The platform is initially targeted at liver diseases.

HydroGene is also federally funded (federal grant work on HT1 / tyrosinemia mouse model) and has been participating in BIO Partnering @ JPM Week 2026. The non-viral gene therapy space is heating up — with Beam, Verve, and Intellia all pivoting toward or specializing in non-viral delivery — and HydroGene is one of the smaller players to watch.

TheraPPI Bioscience — EPFL Spinoff Targeting RAS-MAPK Protein Interactions

TheraPPI Bioscience is a Lausanne-based preclinical biotech (EPFL spinoff) developing small molecules that modify protein-protein interactions in oncology, rare disease, and inflammation. Their first two programs target a novel protein-protein interaction in the RAS-MAPK pathway discovered by the founders and published in Nature Communications. The company holds the French Tech Seed label.

Targeting PPIs with small molecules has been one of the hardest problems in medicinal chemistry — most PPIs have flat, featureless interfaces that don’t bind traditional drug-like molecules well. Companies that crack this — think Nurix, Arvinas, C4 Therapeutics, Monte Rosa — have generally become acquisition targets or large-cap biotechs. TheraPPI is early but the EPFL + Nature Comms publication pedigree is a strong start.

Sapu Nano — Sub-20nm Deciparticle Oncology Platform

Sapu Nano is launching its Deciparticle™ platform — sub-20nm nanomedicine particles engineered for enhanced tumor penetration and programmable biodistribution. The team is led by Dr. Trieu, formerly President and CEO of IGDRASOL (developer of second-generation Abraxane, the paclitaxel nanomedicine approved via a single bioequivalence pathway). Sapu Nano presented the platform at BIO-Europe Spring 2026.

Sapu Nano is now operating as part of Oncotelic (OTCQB: OTLC), the publicly-traded parent. The Deciparticle angle is well-positioned against the next wave of oncology nanomedicine — moving beyond Abraxane’s ~130nm particles into the sub-20nm regime where tumor penetration properties change materially.

SureNano Science — Public-Company Next-Gen GLP-1

SureNano Science (CSE: SURE / OTCQB: SURNF) is a Canadian public life-sciences company that has repositioned around a distinct next-generation GLP-1 built around a novel peptide rather than a small molecule. The company was highlighted as a “One to Watch” by BioMedNewsBreaks on May 21, 2026.

The GLP-1 space is dominated by Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy — both injectable peptides. A differentiated peptide approach (different sequence, different receptor profile, oral or extended-release formulation) is the only realistic entry strategy. Public-company status means SureNano is accessible to retail investors in a way most of the names on this list are not.

Vector Science & Therapeutics — TSXV Listing for Drug-Delivery Medtech

Vector Science & Therapeutics (TSXV: PAIN) listed on the TSX Venture Exchange on April 28, 2026. The company is developing biomechanical devices and active transdermal drug delivery for musculoskeletal tissue regeneration.

Public micro-cap medtech companies rarely make headlines, but Vector is worth noting as one of the few life-sciences vehicles that combine a listed equity with a genuinely novel mechanical + drug-delivery platform for an underserved indication (musculoskeletal regeneration).

Aspera Biomedicines — UCSD Spinoff With $7B-Pedigree Founders

Aspera Biomedicines is the most academically-pedigreed company in this week’s batch. The company is developing rebecsinib, a first-in-class ADAR1 inhibitor targeting cancer stem cells. Aspera is a UCSD spinoff with backing from the UCSD Sanford Stem Cell Institute and a CIRM (California Institute for Regenerative Medicine) grant.

The founders came out of Impact Biomedicines — the company behind fedratinib (now Inrebic), which was acquired by Bristol Myers Squibb for $7B after Impact’s $22M Series A. So the Aspera team has a documented track record of taking a target through to a multi-billion-dollar exit.

What makes Aspera genuinely distinctive is the microgravity-based drug testing the team has run on the International Space Station. Protein crystallization and 3D cell-culture behavior change meaningfully in microgravity, and Aspera has used ISS access to refine ADAR1 inhibitor chemistry in ways that ground-based screening couldn’t. The FDA has cleared rebecsinib for first-in-human trials, putting Aspera in rare company among this week’s batch as a near-clinical-stage biotech.

Cancer stem cells remain one of the most durable unsolved problems in oncology — the hypothesis is that conventional chemotherapy kills bulk tumor cells but spares the self-renewing cancer stem cell population, which reseeds the tumor after treatment. Aspera is one of a small handful of companies (alongside Boston Biomedical, Stemline, and a few others) pursuing CSC-targeted therapeutics directly.

Verge Labs — The Verge Genomics Pivot

Verge Labs (vergelabs.ai) is the new identity of Verge Genomics following the failure of its lead ALS asset in clinical trials. The company had raised approximately $134M+ cumulatively (Series A through C) from backers including Y Combinator, IA Ventures, DFJ, Alumni Ventures, and Tenmile, and was one of the highest-profile AI-native CNS drug discovery companies of the early 2020s.

After the ALS clinical failure, Verge is pivoting from a clinical-stage pipeline to a pure AI platform play — selling the underlying target-ID and patient-stratification models to pharmaceutical partners rather than carrying drugs forward itself. The May 2026 rebrand to Verge Labs reflects that strategic shift. The platform has real technology behind it, but the pivot away from internal drug development is a meaningful change in the AI-native biotech thesis: when the in-house pipeline fails, the platform becomes the product.

Veritas Aortic Solutions — $12M Seed From inQB8 Medical Technologies

Veritas Aortic Solutions closed a $12M seed round in June 2026 to advance transcatheter therapy for complex aortic disease. The company was founded and incubated within inQB8 Medical Technologies (a cardiac medtech incubator) before becoming independent in late 2025. Backers include MedTech angels and Cedars-Sinai IP Co.

The space — transcatheter treatment of the aortic root and ascending aorta — is one of the last major unsolved problems in structural heart. Existing TAVR devices handle the aortic valve; transcatheter solutions for the root and ascending aorta are still pre-commercial. Veritas joins a small competitive set (including JC Medical, Artivion, and several stealth-stage startups) chasing this opportunity.

Neurosoft Bioelectronics — Soft BCI Seed

Neurosoft Bioelectronics is a Geneva-based neurotech building soft brain-computer interfaces for neural data collection, with the goal of enabling minimally-invasive BCI implants for paralysis, epilepsy monitoring, and cognitive research. The company closed an oversubscribed $7.5M seed in May 2026 (total ~$7.7M), is headquartered at Geneva’s Campus Biotech, and has emerged as one of the leading European BCI startups outside of Neuralink and Synchron.

The soft-electrode approach is a meaningful differentiator: rigid BCI electrodes (Neuralink, Blackrock, most academic prototypes) cause chronic tissue damage and signal drift over months. Soft, conformable electrodes promise decades-long signal stability. Neurosoft is one of three European groups (with INBRAIN Neuroelectronics and a Paris group around the BrainGate consortium) that have published compelling animal data on this approach.

ProTgen — Boehringer Ingelheim-Backed Progenitor T-Cell Therapy

ProTgen is a clinical-stage immuno-oncology company developing progenitor T-cell generation from hematopoietic stem cells for cancer immunotherapy, with 21 active clinical trials listed. The company has raised approximately $20M to date, with Boehringer Ingelheim Venture Fund and FACIT as anchor investors.

The progenitor T-cell concept is an interesting one: instead of expanding a patient’s mature T cells (the dominant approach in cell therapy today), ProTgen aims to generate fresh T cells from HSCs, theoretically yielding younger, more persistent cells. Whether that biological advantage translates clinically is the open question — and ProTgen is one of a small set of companies that has actually taken that hypothesis into the clinic.

Raynovent Biotech — $116M Chinese Antiviral Developer

Raynovent Biotech (众生睿创) is a Guangzhou-based clinical-stage antiviral biotech developing small molecules for influenza and other respiratory viruses, including COVID-19. The company has raised approximately $116M across multiple rounds, with a recent Series C led by Guangzhou Hi-tech Investment, Wanlian Securities, BoCom International, and CITIC Medical.

The flu small-molecule space has been quietly competitive since the baloxavir approval in 2018 (Roche/Shionogi XOFLUZA). Raynovent is one of a small handful of Chinese biotechs building a clinical-stage competitive asset against the baloxavir/sitiprevir class, with the regulatory advantage of being able to run trials rapidly in China.

Riverpoint Medical — PE-Backed Medtech Manufacturer

Riverpoint Medical is an Arlington Capital Partners-backed medical device manufacturer specializing in surgical products (orthopedic soft-tissue repair, sports medicine). The company raised $80.1M in acquisition financing in June 2019 and operates as a commercial/revenue-stage business. Not a drug developer, but a meaningful employer in the orthopedic medtech supply chain.

Taewoong Medical — The Olympus Acquisition Story

Taewoong Medical is the Korean gastrointestinal metallic stent manufacturer that Olympus acquired for ~$370M in 2023 — one of the largest pure medtech exits from Korea in recent years. Taewoong bootstrapped from founding to acquisition without external venture capital, building a dominant global position in GI stents. Its inclusion in this week’s diff likely reflects a refresh of Taewoong’s standalone listing following the Olympus integration.

Strivenn — AI Marketing Consultancy for Life Sciences

Strivenn is a life-sciences marketing and AI-governance consultancy — not a drug developer. They’ve been building partnerships with biotech AI strategy firms (recently with Pivotal Scientific to bring AI expertise to the PSL Alliance network). Useful to know about for job seekers on the commercial/marketing side of life sciences; not relevant for the drug-discovery story.

What This Week’s Additions Tell Us About the 2026 Biotech Landscape

Pulling back from the individual companies, three patterns emerge from this week’s 52 additions:

1. Regenerative medicine is having a moment. Cavalry (IGF-1 re-engineering), Tulyp (perfusion-assisted vascular repair), Vector Science (musculoskeletal regeneration), ProTgen (Notch activator thymus reactivation) — four out of 52 are explicitly targeting regeneration rather than inhibition. After a decade of cell-and-gene-therapy hype, the field appears to be settling on a smaller set of bettable regenerative mechanisms.

2. Open data is becoming a strategy, not just a virtue. Crownlands’ release of a 4M-cell living-neuron atlas via CZ CELLxGENE, combined with the broader open-data movement (AlphaFold, ESM-3, TxGemma, Recursion’s public datasets), suggests that for AI-native biotechs, open releases are increasingly part of the moat-building strategy, not a sacrifice. The 2026 playbook is “publish the data, sell the platform.”

3. Japanese and Korean biotechs are surging into the global market. Yoshindo Holdings (Japanese biosimilars), Lupin-Yoshindo joint venture, Wondercel (Frank Fan / Legend founder returning), Sapu Nano, EndoRobotics (Olympus deal), Neopharmed Gentili’s European roll-up — the trans-Pacific life-sciences corridors are thickening visibly. This is partly currency-driven (weaker yen / won makes Japanese and Korean assets cheaper for US and EU acquirers), but it’s also a real maturation of the Japanese biotech ecosystem post-Dexa / PeptiDream.

For job seekers in life sciences, the most active hiring clusters in this week’s batch are:

• Cavalry Biosciences — clinical, regulatory, bioanalytical roles for IGF-1 pipeline
• EndoRobotics — clinical, regulatory, commercial (now under Olympus distribution)
• Neopharmed Gentili — commercial / medical affairs / regulatory for European ORLADEYO rollout
• Wondercel Therapeutics — process development, manufacturing, clinical for off-the-shelf CAR-T
• Crownlands — computational biology, single-cell genomics, ML platform engineering
• Neptune Medical — mechanical engineering, endovascular R&D, regulatory
• Veritas Aortic Solutions — clinical, regulatory, R&D for transcatheter aortic program
• ProTgen — clinical operations, bioprocess, translational science for progenitor T-cell trials
• Neurosoft Bioelectronics — neural engineering, electrode fabrication, clinical research (Geneva)
• Reprogram Biosciences — mRNA process development, in vivo pharmacology, oncology preclinical

We’ll track these as they post roles in our job board over the coming weeks.

---

Sources: weekly industry company-snapshot diff (2026-06-25, comparing 14,321 → 14,334 companies across 60 raw additions and 47 raw removals, 52 genuinely new after database matching), Crunchbase, PitchBook, Endpoints News, Fierce Biotech, MassDevice, BioSpace, businesswire, BioMedNewsBreaks, company press releases, peer-reviewed publications.